Arbor Investment Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-17,950
Closed -$1.32M 117
2025
Q3
$1.32M Buy
+17,950
New +$1.19M 0.17% 43
2024
Q4
Sell
-17,950
Closed -$1.03M 111
2024
Q3
$1.03M Buy
+17,950
New +$1.03M 0.14% 43
2024
Q2
Sell
-17,950
Closed -$730K 104
2024
Q1
$730K Hold
17,950
0.11% 50
2023
Q4
$663K Hold
17,950
0.1% 50
2023
Q3
$686K Hold
17,950
0.12% 44
2023
Q2
$647K Hold
17,950
0.11% 48
2023
Q1
$686K Hold
17,950
0.13% 48
2022
Q4
$1.02M Buy
+17,950
New +$919K 0.21% 39
2022
Q3
Sell
-17,950
Closed -$790K 93
2022
Q2
$790K Hold
17,950
0.17% 41
2022
Q1
$716K Hold
17,950
0.14% 43
2021
Q4
$722K Hold
17,950
0.14% 45
2021
Q3
$730K Hold
17,950
0.15% 42
2021
Q2
$815K Hold
17,950
0.17% 38
2021
Q1
$748K Hold
17,950
0.17% 41
2020
Q4
$767K Hold
17,950
0.18% 38
2020
Q3
$472K Hold
17,950
0.12% 49
2020
Q2
$481K Hold
17,950
0.13% 45
2020
Q1
$323K Hold
17,950
0.11% 58
2019
Q4
$318K Hold
17,950
0.09% 67
2019
Q3
$278K Hold
17,950
0.08% 68
2019
Q2
$308K Buy
+17,950
New +$290K 0.1% 62

Other funds holding HALO

Arbor Investment Advisors's HALO Position: Q4 2025 in Review

Arbor Investment Advisors sold out of Halozyme (HALO) in Q4 2025, closing a stake of 17,950 shares — an estimated $1.32M sold.

Arbor Investment Advisors first reported a position in HALO in Q2 2019 and held it in 21 quarters. The position peaked at $1.32M in Q3 2025. 617 funds tracked by Wall St. Rank hold HALO as of Q4 2025.

  • Arbor Investment Advisors reported no remaining Halozyme position as of Q4 2025 after selling out during the quarter.
  • Arbor Investment Advisors sold 17,950 Halozyme shares in Q4 2025, an estimated $1.32M.
  • Arbor Investment Advisors first reported a position in Halozyme in Q2 2019 and held it in 21 quarters.
  • Arbor Investment Advisors's Halozyme position peaked at $1.32M in Q3 2025.
  • 617 funds tracked by Wall St. Rank held Halozyme as of Q4 2025.

Based on Arbor Investment Advisors's 13F filing for Q4 2025, filed 23 Jan 2026.